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Abstract. Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS) is an autosomal dominant cerebral white
matter degeneration leading to progressive cognitive and motor dysfunction. The peripheral nervous system is generally spared.
Recently, mutations in the colony-stimulating factor-1 receptor (CSF1R) gene have been shown to be associated with HDLS.
Here we report a new case of HDLS, carrying a mutation in CSF1R and manifesting rapidly progressive dementia and peripheral
neuropathy.
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INTRODUCTION
Hereditary diffuse leukoencephalopathy with
axonal spheroids (HDLS) is a rare autosomal domi-
nant disorder characterized by cerebral white matter
degeneration with focal swellings of axons. Since
the original HDLS kindred identified in Sweden
[1], both hereditary and sporadic cases have been
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described. Onset is usually in the fourth to fifth
decade of life. The clinical picture is characterized by
behavioral and cognitive changes [2], often associated
with unsteady gait, urinary incontinence, seizures,
and involuntary movements. Dementia, abulia, dys-
phagia, and severe motor dysfunction appear later.
Brain magnetic resonance imaging (MRI) shows
nonspecific frontotemporal leukoencephalopathy with
concomitant cerebral atrophy. Cerebral white matter
abnormalities are initially patchy and asymmetri-
cal, and later become confluent and symmetrical.
Neuropathology shows a loss of myelin and axons,
gliosis, and macrophages in the presence of axonal
swellings (spheroids) [3]. The peripheral nervous
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Fig. 1. MRI: Neuroimaging of the patient. a) Fluid attenuated inversion recovery axial magnetic resonance image (MRI) shows brain atrophy,
ventriculomegaly, and symmetrical hyperintensity of the periventricular white matter, with predominant parieto-occipital involvement. Subcor-
tical U-fibers are relatively spared. b) T1-weighted sagittal MRI shows brain atrophy and severe thinning of the corpus callosum. c) T2-weighted
coronal MRI shows a hyperintense signal in the pyramidal tracts.
system is generally spared. Recently, mutations in the
colony stimulating factor 1 receptor (CSF1R) gene
were identified as the genetic basis of HDLS [4]. Most
consist of missense substitutions within the protein
tyrosine kinase domain, predicted to lead to a loss of
autophosphorylation. To date, more than 20 different
mutations have been detected in familial cases, among
which, three unrelated Italian patients with HDLS,
described by our group [5].
Here we report a new case of HDLS, with a novel
CSF1R mutation, in which the classical symptoms
were associated with peripheral neuropathy
CASE REPORT
The index case was a 35-year-old man with a one-
year history of depression, abulia, and apathy, followed
by left hemiparesis. A few months into his illness, he
manifested early signs of cognitive impairment, with
deficits in short term memory, concentration, and logi-
cal sequencing. Language and long term memory were
spared.
The patient’s father had suffered a similar neurolog-
ical illness, beginning in his third decade and leading to
progressive mental and motor deterioration with death
at age 34.
The patient was first hospitalized at age 34: brain
MRI showed multifocal leukoencephalopathy and
severe atrophy of the corpus callosum. Cerebrospinal
fluid analysis revealed slight protein elevation and
an absence of oligoclonal IgG bands. A diagno-
sis of primary progressive multiple sclerosis was
entertained and the patient received immunotherapy
with intravenous methylprednisolone and interferon
beta-1a (IFN-1a). However, his cognitive functions
rapidly declined and he developed incontinence and
dysarthria. He stopped working and became inconsis-
tent in performing regular daily activities.
When he was admitted to our hospital at age
35, his condition was further worsened. He was
bedridden, mute, unable to perform purposeful move-
ments, and had severe mixed dysphagia requiring
percutaneous endoscopic gastrostomy. Neurological
examination showed spastic tetraparesis with large
joint contractures, cortical blindness, and bowel incon-
tinence. Tendon reflexes were diffusely weak and
all four distal limbs were severely atrophic. Labo-
ratory tests, including lactate, lysosomal enzymes,
ceruloplasmin, urinary oligosaccharides, and urinary
sulfatides, were all negative. A thrombotic risk profile
and autoantibody screening were also negative. Brain
MRI revealed severe T2/ FLAIR-hyperintensities in
the periventricular deep white matter, thinning of
the corpus callosum and marked cortical atrophy
(Fig. 1). Electroencephalography showed frontotem-
poral slowing. A peripheral nerve conduction study
and electromyography revealed marked sensorimotor
axonal neuropathy with predominant involvement of
the motor nerves (Supplementary Table 1). To date the
patient is in a vegetative state.
GENETIC ANALYSIS
After obtaining informed consent, genomic DNA
was extracted from peripheral blood leukocytes using
the Puregene DNA isolation kit or the Qiamp blood
kit (Qiagen, Mannheim, Germany). Genomic DNA
was amplified by PCR using sets of specific primers,
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Fig. 2. Identification of the c.2539G>A CSF1R mutation. A) Sequencing chromatogram showing the heterozygous c.2539G>A missense
mutation in the exon 19 of the CSF1R gene. The mutation changes a Glutamic acid codon into Lysine at position 847. B) Glutamic acid 847
(p.E847) conservation among CSF1R orthologues and CSF1/PDGF receptor paralogues. C) Mutation pathogenicity of the p.Glu847Lys was
assessed using eight software programs: SIFT, PolyPhen-2, I-Mutant 2.0, Mutation Tasting, PMUT, SNAP-F, PON-P, and PHD-SNP.
in order to investigate the coding sequences and
intron/exon boundaries of CSF1R (NM 005211.3).
Sequence analysis was carried out using SeqScape ver-
sion 2.5 software (Applied Biosystems).
A novel mutation c.2539G>A, leading to the amino
acid substitution p.Glu847Lys, was revealed in exon 19
of the CSF1R gene. This amino acid is located within
the conserved intracellular tyrosine kinase domain
of the CSF1R gene and has not been reported pre-
viously (HGMD® Human Gene Mutation Database,
dbSNP, 1000Genomes, EVS). p.Glu847Lys mutation,
investigated by in silico analysis, was predicted to be
pathogenic (Fig. 2).
CONCLUSION
We report a patient with a genetically confirmed
HDLS initially presenting with behavioral changes,
followed by rapid progressive cognitive and motor
decline. Peripheral neuropathy was evident at elec-
trophysiological examination. Involvement of the
peripheral nervous system has never been previously
reported in HDLS. In our patient, the most common
toxic and metabolic causes of polyneuropathy were
ruled out, even if we could not perform a nerve biopsy.
Interestingly, axonal spheroids have recently been
found in the skin nerves of HDLS patients, suggesting
a more widespread nervous system involvement and
possibly providing new insights into the etiopathology
of HDLS [6].
Another point of interest was the MRI find-
ings, which showed cerebral atrophy with parieto-
occipitally predominant T2 white matter hyperin-
tensity and areas of restricted diffusion, a lack of
gadolinium enhancement, thinning of the corpus callo-
sum, and cortico-spinal involvement along the whole
length of the pyramidal tract, which correlated with
motor deterioration toward tetraplegia [7]. The clin-
ical and neuroimaging findings were very similar to
those of previously reported cases of HDLS. However,
our patient presented a more severe involvement of the
parieto-occipital white matter, responsible of the corti-
cal blindness, as previously described in only another
case in the literature [8].
The c.2539G>A missense mutation identified in our
patient results in a missense change Glu847-to-Lys.
As all the other mutations in CSF1R gene described
to date, this substitution affects a highly evolutionary
conserved residue located in the intracellular tyrosine
kinase domain. Bioinformatics analyses and the con-
servation among paralogues gene support a pathogenic
role of the c.2539G>A.
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Finally, we want to underline that all the described
Italian families originated from the South of Italy. This
patient is from Puglia; the three previously reported
families [5] included one from Puglia and the other two
from Campania and Sicily, respectively. The different
mutations in all families exclude common ancestors.
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